Cargando…

Risk of progression of Barrett's esophagus in patients with cirrhosis

AIM: To study Barrett’s esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS: Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2...

Descripción completa

Detalles Bibliográficos
Autores principales: Apfel, Tehilla, Lopez, Rocio, Sanaka, Madhusudhan R, Thota, Prashanthi N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434434/
https://www.ncbi.nlm.nih.gov/pubmed/28566888
http://dx.doi.org/10.3748/wjg.v23.i18.3287
_version_ 1783237046605709312
author Apfel, Tehilla
Lopez, Rocio
Sanaka, Madhusudhan R
Thota, Prashanthi N
author_facet Apfel, Tehilla
Lopez, Rocio
Sanaka, Madhusudhan R
Thota, Prashanthi N
author_sort Apfel, Tehilla
collection PubMed
description AIM: To study Barrett’s esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS: Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2000 to 12/1/2015 at Cleveland Clinic were included. Cirrhotic patients were matched 1:4 to BE controls without cirrhosis. Age, gender, race, BE length, hiatal hernia size, Child-Pugh (CP) class and histological findings were recorded. Cases and controls without high-grade dysplasia (HGD)/EAC and who had follow-up endoscopies were studied for incidence of dysplasia/EAC and to assess progression rates. Univariable conditional logistic regression was done to assess differences in baseline characteristics between the two groups. RESULTS: A total of 57 patients with cirrhosis and BE were matched with 228 controls (BE without cirrhosis). The prevalence of dysplasia in cirrhosis and controls were similar with 8.8% vs 12% with low grade dysplasia (LGD) and 12.3 % vs 19.7% with HGD or EAC (P = 0.1). In the incidence cohort of 44 patients with median follow-up time of 2.7 years [interquartile range 1.0, 4.8], there were 7 cases of LGD, 2 cases of HGD, and 2 cases of EAC. There were no differences in incidence rates of HGD/EAC in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person- years, P = 0.8). In LGD, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person- years, P = 0.51). A significant association was found between a higher CP class and neoplastic progression of BE in cirrhotic patients (HR =7.9, 95%CI: 2.0-30.9, P = 0.003). CONCLUSION: Cirrhotics with worsening liver function are at increased risk of progression of BE. More frequent endoscopic surveillance might be warranted in such patients.
format Online
Article
Text
id pubmed-5434434
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-54344342017-05-31 Risk of progression of Barrett's esophagus in patients with cirrhosis Apfel, Tehilla Lopez, Rocio Sanaka, Madhusudhan R Thota, Prashanthi N World J Gastroenterol Case Control Study AIM: To study Barrett’s esophagus (BE) in cirrhosis and assess progression to esophageal adenocarcinoma (EAC) compared to non-cirrhotic BE controls. METHODS: Cirrhotic patients who were found to have endoscopic evidence of BE confirmed by the presence of intestinal metaplasia on histology from 1/1/2000 to 12/1/2015 at Cleveland Clinic were included. Cirrhotic patients were matched 1:4 to BE controls without cirrhosis. Age, gender, race, BE length, hiatal hernia size, Child-Pugh (CP) class and histological findings were recorded. Cases and controls without high-grade dysplasia (HGD)/EAC and who had follow-up endoscopies were studied for incidence of dysplasia/EAC and to assess progression rates. Univariable conditional logistic regression was done to assess differences in baseline characteristics between the two groups. RESULTS: A total of 57 patients with cirrhosis and BE were matched with 228 controls (BE without cirrhosis). The prevalence of dysplasia in cirrhosis and controls were similar with 8.8% vs 12% with low grade dysplasia (LGD) and 12.3 % vs 19.7% with HGD or EAC (P = 0.1). In the incidence cohort of 44 patients with median follow-up time of 2.7 years [interquartile range 1.0, 4.8], there were 7 cases of LGD, 2 cases of HGD, and 2 cases of EAC. There were no differences in incidence rates of HGD/EAC in nondysplastic BE between cirrhotic cases and noncirrhotic controls (1.4 vs 1.1 per 100 person- years, P = 0.8). In LGD, cirrhotic patients were found to have higher rates of progression to HGD/EAC compared to control group though this did not reach statistical significance (13.7 vs 8.1 per 100 person- years, P = 0.51). A significant association was found between a higher CP class and neoplastic progression of BE in cirrhotic patients (HR =7.9, 95%CI: 2.0-30.9, P = 0.003). CONCLUSION: Cirrhotics with worsening liver function are at increased risk of progression of BE. More frequent endoscopic surveillance might be warranted in such patients. Baishideng Publishing Group Inc 2017-05-14 2017-05-14 /pmc/articles/PMC5434434/ /pubmed/28566888 http://dx.doi.org/10.3748/wjg.v23.i18.3287 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Control Study
Apfel, Tehilla
Lopez, Rocio
Sanaka, Madhusudhan R
Thota, Prashanthi N
Risk of progression of Barrett's esophagus in patients with cirrhosis
title Risk of progression of Barrett's esophagus in patients with cirrhosis
title_full Risk of progression of Barrett's esophagus in patients with cirrhosis
title_fullStr Risk of progression of Barrett's esophagus in patients with cirrhosis
title_full_unstemmed Risk of progression of Barrett's esophagus in patients with cirrhosis
title_short Risk of progression of Barrett's esophagus in patients with cirrhosis
title_sort risk of progression of barrett's esophagus in patients with cirrhosis
topic Case Control Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434434/
https://www.ncbi.nlm.nih.gov/pubmed/28566888
http://dx.doi.org/10.3748/wjg.v23.i18.3287
work_keys_str_mv AT apfeltehilla riskofprogressionofbarrettsesophagusinpatientswithcirrhosis
AT lopezrocio riskofprogressionofbarrettsesophagusinpatientswithcirrhosis
AT sanakamadhusudhanr riskofprogressionofbarrettsesophagusinpatientswithcirrhosis
AT thotaprashanthin riskofprogressionofbarrettsesophagusinpatientswithcirrhosis